Effectiveness And Safety Of Tirofiban Hcl For Patients With Non-ST-Elevation Acute Coronary Syndrome: A Meta-analysis

Objective:To systematically review the effectiveness and safety of tirofiban for patients with non ST-elevation acute coronary syndromes(NSTE-ACS).Methods:useing the computer to search the databases in both English and Chinese,including The Cochrane Library(Issue 9, 2015), Pub Med, EMbase, CBM, CNKI, VIP and Wan Fang Data from 1995 to 2015 to collect randomized controlled trials(RCTs) about tirofiban for NSTE-ACS patients in Early medicine conservative treatment.Two reviewers independently screened literature according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality of included studies.Meta-analysis was then conducted using Rev Man 5.3 software.Results:A total of 11 RCTs were enrolled involving 6483 patients.The results of meta analysi showed that:(1)the incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group(during One week:OR=0.42,95%CI(0.29,0.61),P<0.000 01) and the incidences of cardiovascular events of composite endpoints in the trial group were lower than that in the control group(during 3days:OR=0.46,95%CI(0.31,0.67),P<0.000 01).(2)the incidence rate of bleeding in the trial group was higher than that in the control group(OR=1.49,95%CI(1.12,1.98)P=0.006).Conclusion:Compared with routine drugs used alone, tirofiban has better therapeutic effe cts in Early medicine conservative treatment for patients with NSTE-ACS, but theincidence of bleeding is relatively high.